` ADMA (ADMA Biologics Inc) vs S&P 500 Comparison - Alpha Spread

ADMA
vs
S&P 500

Over the past 12 months, ADMA has significantly outperformed S&P 500, delivering a return of 62% compared to the S&P 500's 9% growth.

Stocks Performance
ADMA vs S&P 500

Loading
ADMA
S&P 500
Add Stock

Performance Gap
ADMA vs S&P 500

Loading
ADMA
S&P 500
Difference
www.alphaspread.com

Performance By Year
ADMA vs S&P 500

Loading
ADMA
S&P 500
Add Stock

Competitors Performance
ADMA Biologics Inc vs Peers

S&P 500
ADMA
ABBV
AMGN
GILD
VRTX
Add Stock

ADMA Biologics Inc
Glance View

Economic Moat
Wide
Market Cap
4.3B USD
Industry
Biotechnology

ADMA Biologics Inc. operates at the intersection of biotechnology and pharmaceuticals with a dedicated focus on the development and commercialization of plasma-based therapeutics. Established with a mission to address unmet medical needs, particularly in immune-compromised patients, ADMA leverages its specialized expertise in the collection, manufacturing, and distribution of immunoglobulins. The company owns and operates FDA-approved source plasma collection facilities under the name ADMA BioCenters, which supply plasma as a key raw material. This plasma serves as the foundation for their suite of FDA-approved products aimed at treating immune deficiencies and other related disorders. Central to ADMA's business model is its vertically integrated approach, which enables the company to maintain stringent oversight from plasma collection to product development and distribution. By controlling the entire supply chain, ADMA can achieve cost efficiencies and ensure high-quality standards, crucial for patient safety and regulatory compliance. The company generates revenue primarily through the sale of its flagship products, such as BIVIGAM and ASCENIV, which are used for immune globulin replacement therapy. ADMA also broadens its revenue streams through strategic partnerships and by offering third-party contract manufacturing services. This diversified approach positions the company robustly within the competitive biopharmaceutical landscape, while striving for growth through research and development of new plasma-derived therapies.

ADMA Intrinsic Value
13.09 USD
Overvaluation 27%
Intrinsic Value
Price
Back to Top